In August 2021, Carrick Therapeutics announced it was granted Fast Track designation for CT7001 in combination with the antioestrogen fulvestrant for the treatment of CDK4/6i-resistant hormone receptor-positive, HER2-negative advanced breast cancer and that it will begin evaluating CT7001 in combination with giredestrant, a next-generation selective oestrogen receptor degrader, in collaboration with Roche (NCT04802759). This evidence concerns the gene CDK4 and breast carcinoma.